“B” Best? Handicapping The Democratic Field For Pharma
Executive SummaryDrug pricing is bound to be a dominant theme in the 2020 Democratic primaries and US Presidential election. But there are some differences in the crowded field of candidates, including several who are more likely to emphasis protecting innovation alongside controlling prices.
You may also be interested in...
Hillary Clinton is reviving an idea she first endorsed in 1993: a drug price oversight board, but the focus has changed. While the pharma industry isn’t about to embrace any federal oversight board, the new Clinton plan is a lot less threatening than the old one.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.
White House Council of Economic Advisors says US House drug price “negotiation” bill will reduce the number of innovative medicines by 100 over a decade; the Congressional Budget Office says more like 8-15. Both analyses miss the point – but also show that industry is losing a crucial piece of political ground.